文献速递MDS 与骨髓增殖性肿瘤白血病

BLAST:一种全球适用且分子适应性强的慢性粒单核细胞白血病生存模型

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia.
PubMed 文献 · Blood · 2025-01-01

研究基于457例有分子注释的慢性粒单核细胞白血病(CMML)患者,开发了以临床变量为基础的BLAST生存模型,并整合突变与核型构建BLAST-mol模型,两个模型均经2个外部队列验证。

要点

  • BLAST临床模型基于循环原始细胞≥2%、白细胞≥13×10^9/L和贫血程度分层。
  • BLAST低危0分中位OS 63个月,中危1分28个月,高危2-4分13个月。
  • BLAST-mol在BLAST基础上加入3层分子风险评分,3/5年AUC为0.80/0.86。

核心结论

  • 本研究提出一种易于实施、全球适用且分子适应性强的CMML风险模型。

研究设计与样本

  • 研究纳入457例有分子注释的CMML患者,开发并验证生存模型。
  • BLAST和BLAST-mol随后通过2个独立外部队列进行验证。

主要发现

  • 多变量分析确定循环原始细胞≥2%(1分)、白细胞≥13×10^9/L(1分)、重度贫血(2分)或中度贫血(1分)为总生存期的首选风险变量。
  • BLAST低危(0分)中位OS 63个月;中危(1分)中位OS 28个月,HR 2.2(95%CI 1.6-3.0);高危(2-4分)中位OS 13个月,HR 5.4(95%CI 4.1-7.3)。
  • BLAST低危、中危、高危的3年/5年OS率分别为68%/53%、43%/18%、12%/1%。
  • BLAST模型3年/5年AUC为0.77/0.85,与分子CMML特异性预后评分系统(AUC 0.73/0.75)和国际预后评分系统-分子(AUC 0.73/0.74)相当。
  • BLAST-mol模型3年/5年AUC为0.80/0.86。

关键数值与推荐

  • BLAST评分:循环原始细胞≥2%计1分,白细胞≥13×10^9/L计1分,重度贫血计2分,中度贫血计1分。
  • BLAST风险分层:低危0分,中危1分,高危2-4分。
  • BLAST-mol包含BLAST临床风险变量和3层分子风险评分。
  • 多变量分析中PHF6MUT和TET2MUT为「有利」因素;DNMT3AMUT、U2AF1MUT、BCORMUT、SETBP1MUT、ASXL1MUT、NRASMUT、PTPN11MUT、RUNX1MUT、TP53MUT和不良核型为「不利」因素。
  • 原始细胞转化的独立风险因素包括DNMT3AMUT、ASXL1MUT、PHF6WT、白细胞≥13×10^9/L、循环原始细胞≥2%或骨髓原始细胞≥10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We sought to develop a survival model in chronic myelomonocytic leukemia (CMML) that is primarily based on clinical variables and examine additional impact from mutations and karyotype. A total of 457 molecularly annotated patients were considered. Multivariable analysis identified circulating blasts ≥2% (1 point), leukocytes ≥13 × 109/L (1 point), and severe (2 points) or moderate (1 point) anemia as preferred risk variables in developing a clinical risk stratification tool for overall survival (OS), acronymized to "BLAST": low risk (0 points; median, 63 months); intermediate risk (1 point; median, 28 months; hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.6-3.0), and high risk (2-4 points; median, 13 months; HR, 5.4; 95% CI, 4.1-7.3); the corresponding 3/5-year OS rates were 68%/53%, 43%/18%, and 12%/1%. BLAST model performance (area under the receiver operating characteristic curve [AUC] 0.77/0.85 at 3/5 years) was shown to be comparable to that of the molecular CMML-specific prognostic scoring system (AUC 0.73/0.75) and the international prognostic scoring system-molecular (AUC 0.73/0.74). Multivariable analysis of mutations and karyotype identified PHF6MUT and TET2MUT as being "favorable" and DNMT3AMUT, U2AF1MUT, BCORMUT, SETBP1MUT, ASXL1MUT, NRASMUT, PTPN11MUT, RUNX1MUT, TP53MUT, and adverse karyotype, "unfavorable." Molecular information was subsequently encoded in a combined clinical-molecular risk model (BLAST-mol; AUC 0.80/0.86 at 3/5 years) that included the aforementioned BLAST clinical risk variables and a 3-tiered molecular risk score. BLAST and BLAST-mol were subsequently validated by 2 separate external cohorts. Independent risk factors for blast transformation included DNMT3AMUT, ASXL1MUT, PHF6WT, leukocytes ≥13 × 109/L, and ≥2% circulating or ≥10% bone marrow blasts. The current study proposes an easy-to-implement, globally applicable, and molecularly adaptive risk model for CMML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Fathima S, Abdelmagid M, et al. BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia. Blood. 2025. PMID: 40332442. doi:10.1182/blood.2024027170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。